Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Change in Cash (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Change in Cash for 4 consecutive years, with $38.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Cash rose 279.5% to $38.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.2 million, a 117.63% increase, with the full-year FY2025 number at $10.2 million, up 117.63% from a year prior.
  • Change in Cash was $38.2 million for Q4 2025 at Spruce Biosciences, up from -$5.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $49.2 million in Q1 2023 to a low of -$25.6 million in Q3 2022.
  • A 4-year average of $373625.0 and a median of -$7.5 million in 2025 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: skyrocketed 353.66% in 2023, then tumbled 829.95% in 2024.
  • Spruce Biosciences' Change in Cash stood at $2.9 million in 2022, then plummeted by 185.84% to -$2.5 million in 2023, then tumbled by 765.58% to -$21.3 million in 2024, then soared by 279.5% to $38.2 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Change in Cash are $38.2 million (Q4 2025), -$5.7 million (Q3 2025), and -$9.2 million (Q2 2025).